Outlook Therapeutics, Inc. (OTLK)

8.17 -0.12 (-1.45%) At close: 04:00PM EDT

Outlook Therapeutics, Inc.

Building F
Suite 320 485 Route 1 South
Iselin, NJ 08852
United States
609 619 3990
https://www.outlooktherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 24

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ralph H. Thurman	Independent Executive Chairman	207.5k	N/A	1949
Mr. C. Russell Trenary III	President, CEO & Director	610.9k	N/A	1958
Mr. Lawrence A. Kenyon CPA	Executive VP, CFO, Treasurer, Company Secretary & Director	N/A	N/A	1966
Mr. Jeffrey Evanson	Chief Commercial Officer	451.17k	N/A	1969
Ms. Alicia Tozier	Senior Vice President, Marketing & Market Access	N/A	N/A	N/A
Mr. Joel Prieve	Senior Vice President of Licensing and M&A	N/A	N/A	N/A
Dr. Surendra Sharma M.D.	Senior Vice President of Medical Affairs	N/A	N/A	N/A
Dr. Jennifer M. Kissner Ph.D.	Senior Vice President of Clinical Development & Regulatory Affairs	N/A	N/A	N/A
Mr. Jedd Comiskey	Senior VP - Head of Europe	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Corporate governance

Outlook Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.